Pyrig L A, Lapchinskaia I I, Belitskaia G A, Lezhen T I, Iakovenko A M, Ishchenko V M, Fedorova N E
Klin Med (Mosk). 1996;74(2):32-5.
3-week heparin treatment (25000 U/day) of 38 patients with diabetic glomerulosclerosis (DGS) produced positive results in 31 of them, was ineffective in 5 patients and induced complications in 2 cases. Prognostic criteria of heparin treatment efficacy basing on hemostatic changes on day 7 have been developed. Hemostasis was controlled most effectively in patients receiving heparin by a new graphic turbidimetric method capable of objective registration of clotting and fibrinolysis in one plasma portion. Because individual sensitivity to heparin widely varies and this variability manifests as early as first days of treatment, control over hemostasis system in heparin day dose 25000 U/day is advisable before treatment, on treatment day 3, 7 and on aftertreatment day 2.
对38例糖尿病肾小球硬化症（DGS）患者进行为期3周的肝素治疗（25000单位/天），其中31例取得阳性结果，5例无效，2例出现并发症。已制定基于第7天止血变化的肝素治疗疗效的预后标准。通过一种新的图形比浊法能在一份血浆中客观记录凝血和纤溶情况，从而最有效地控制接受肝素治疗患者的止血情况。由于个体对肝素的敏感性差异很大，且这种差异在治疗的最初几天就已显现，因此建议在治疗前、治疗第3天、第7天以及治疗后第2天对接受25000单位/天肝素治疗的患者的止血系统进行监测。
